PRAX Logo

Praxis Precision Medicines, Inc. (PRAX) 

NASDAQ$36.99-1.94 (-4.98%)
Market Cap
$784.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
785 of 924
Rank in Industry
441 of 527

PRAX Insider Trading Activity

PRAX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$1,085,1462100

Related Transactions

Mastrocola LaurenPrincipal Accounting Officer0$01$424,318$-424,318
Nemiroff AlexGeneral Counsel and Secretary0$01$660,827$-660,827

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential â€¦

Insider Activity of Praxis Precision Medicines, Inc.

Over the last 12 months, insiders at Praxis Precision Medicines, Inc. have bought $0 and sold $1.09M worth of Praxis Precision Medicines, Inc. stock.

On average, over the past 5 years, insiders at Praxis Precision Medicines, Inc. have bought $2.55M and sold $8.67M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 14,500 shares for transaction amount of $25,375 was made by DeSimone Jill (director) on 2023‑10‑05.

List of Insider Buy and Sell Transactions, Praxis Precision Medicines, Inc.

2024-11-14SaleNemiroff AlexGeneral Counsel and Secretary
8,239.33
0.0451%
$80.20$660,827-3.72%
2024-11-14SaleMastrocola LaurenPrincipal Accounting Officer
5,188.34
0.029%
$81.78$424,318-3.72%
2023-10-05PurchaseDeSimone Jilldirector
14,500
0.0118%
$1.75$25,375+82.67%
2023-06-27PurchaseSouza MarcioChief Executive Officer
10,000
0.0186%
$1.06$10,587+52.34%
2023-03-24PurchaseMITCHELL DEAN Jdirector
50,000
0.0964%
$0.84$41,815+43.72%
2023-03-24PurchaseKelly Timothy EdwinChief Financial Officer
8,000
0.0161%
$0.87$6,998+43.72%
2023-03-23PurchaseSouza MarcioChief Executive Officer
70,001.75
0.1332%
$0.86$60,366+37.08%
2022-06-16PurchaseMastrocola LaurenPrincipal Accounting Officer
3,000
0.0065%
$1.93$5,775+14.95%
2022-06-13PurchaseNemiroff AlexGeneral Counsel and Secretary
7,500
0.0147%
$1.63$12,225+22.53%
2022-06-09PurchaseKelly Timothy EdwinChief Financial Officer
10,000
0.0221%
$1.76$17,650+27.43%
2022-06-08PurchaseSouza MarcioChief Executive Officer
27,000
0.0609%
$1.85$49,888+23.89%
2022-06-08PurchaseMITCHELL DEAN J
25,000
0.0551%
$1.81$45,188+23.89%
2021-10-06SaleBSOF Parallel Master Fund L.P.10 percent owner
400,000
0.8%
$17.50$7M-45.09%
2021-10-05SaleBSOF Parallel Master Fund L.P.10 percent owner
23,946
0.0534%
$19.15$458,566-43.95%
2021-10-01SaleBSOF Parallel Master Fund L.P.10 percent owner
22,600
0.0498%
$19.13$432,338-43.44%
2021-08-31PurchaseKelly Timothy EdwinChief Financial Officer
3,905
0.0086%
$19.48$76,069-35.35%
2021-08-23SaleBSOF Parallel Master Fund L.P.10 percent owner
352,396
0.7552%
$19.00$6.7M-33.99%
2021-08-18SaleBSOF Parallel Master Fund L.P.10 percent owner
3,000
0.0067%
$15.88$47,640-17.40%
2021-08-18PurchaseSouza MarcioChief Executive Officer
9,542
0.021%
$15.79$150,668-17.40%
2021-08-12SaleBSOF Parallel Master Fund L.P.10 percent owner
10,060
0.0226%
$13.92$140,035-4.00%
Total: 26
*Gray background shows transactions not older than one year

Insider Historical Profitability

29.52%
Nemiroff AlexGeneral Counsel and Secretary
10301
0.0511%
$401,004.9711+22.53%
Mastrocola LaurenPrincipal Accounting Officer
5613
0.0278%
$218,500.7011+14.95%
Vitorovic Stefandirector
2939329
14.5776%
$114.43M10+1.23%
MITCHELL DEAN Jdirector
75000
0.372%
$2.92M20+33.8%
Kelly Timothy EdwinChief Financial Officer
46416
0.2302%
$1.81M30+35.57%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$3,596,906
112
13.42%
$635.29M
$7,929,017
58
21.56%
$788.11M
$97,176
41
42.84%
$782.59M
$28,907,358
35
41.41%
$914.6M
$61,752,931
34
14.31%
$749.88M

PRAX Institutional Investors: Active Positions

Increased Positions93+66.43%5M+26.98%
Decreased Positions62-44.29%2M-12.04%
New Positions38New625,470New
Sold Out Positions11Sold Out220,454Sold Out
Total Postitions171+22.14%22M+14.94%

PRAX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Cormorant Asset Management, Lp$64,816.008.47%1.69M+823,219+94.62%2024-12-31
Blackrock, Inc.$55,982.007.31%1.46M+160,010+12.29%2024-12-31
Perceptive Advisors Llc$50,902.006.65%1.33M+165,700+14.23%2024-12-31
Price T Rowe Associates Inc /Md/$46,262.006.04%1.21M+88,442+7.9%2024-12-31
Morgan Stanley$44,540.005.82%1.16M+1M+1,345.37%2024-12-31
Vanguard Group Inc$40,716.005.32%1.06M+24,645+2.37%2024-12-31
Capital Research Global Investors$38,034.004.97%993,569-3,525-0.35%2024-12-31
Vr Adviser, Llc$37,897.004.95%989,985+283,854+40.2%2024-12-31
Janus Henderson Group Plc$35,582.004.65%929,523+405,957+77.54%2024-12-31
State Street Corp$29,424.003.84%768,655-20,969-2.66%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.